01Turn Therapeutics reported Q3 2026 EPS of -$0.21, missing the consensus estimate of -$0.09 by $0.12 per share.
02The 133% miss relative to consensus estimates represents a notable negative deviation that often triggers analyst revisions.
03The company's stock trades at $9.58 with a $96.1M market capitalization following the earnings release.
04Turn Therapeutics has missed earnings estimates in three of the last four quarters, with Q2 showing a -900% surprise.
05Investors should evaluate this miss against year-over-year and sequential trends to determine if the business is accelerating, stabilizing, or decelerating.
Earnings Results
Turn Therapeutics (NASDAQ:TTRX) reported quarterly earnings results on November 09, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.21, missing the consensus estimate of $-0.09 by $0.12 per share. Revenue came in at , meeting the estimate of .
Company Overview
Turn Therapeutics's stock moved following the earnings release. The stock currently trades at $9.58 with a market capitalization of $96.1M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 133% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Turn Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.